Cytomegalovirus Infection in Kidney Transplant Recipients: Evolution of Approach Through Three Eras

Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies

“…Former studies reported MMF and anti-lymphocyte induction therapy as significant risk factors for CMV infection [24][25][26]. Interestingly, more recent studies have suggested a protective effect of MMF in this setting [27,28]. In our patient cohort, the choice of immunosuppressive regimen including induction therapy was not related to the incidence of CMV infection.…”

High Incidence of Cytomegalovirus Disease in D+/R− Heart Transplant Recipients Shortly After Completion of 3 Months of Valganciclovir Prophylaxis

“…14 Similar to our experience, the majority of CMV infections in their kidney transplant population occurred within the first 3 months after cessation of CMV prophylaxis. 7,14 In that population, 24 weeks of oral ganciclovir prophylaxis was associated with a lower incidence of CMV disease compared with a 12-week course. 7 In lung transplant recipients, Zamora et al reported outcomes of a prolonged period of CMV prophylaxis.…”

Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease

“…The majority of studies addressing late‐CMV disease include many D+/R− pairs, mixed induction therapy as well as kidney and non‐kidney transplants . Hardinger et al.…”